Bruker Announces Novel NMR Phenomics Research Capabilities
New B.I.QUANT-UR™ Module for Automated and Reproducible Quantification of up to 150 Metabolites in Urine in 80-100 Samples/Day Enhances Bruker's NMR IVDr Platform for Translational Phenomics Research
Urine is an important body fluid in metabolomics due to little interference with metabolite binding proteins. Large sample cohorts in clinical studies demand automated solutions capable of measuring and analyzing with highest information content and quantitative reproducibility. The new B.I.QUANT-UR module is a completely automated solution that can replace multiple conventional analysis methods.
Bruker's Avance IVDr platform is optimized for clinical and translational research. It uses standard operating procedures (SOPs) in B.I.Methods (https://www.bruker.com/
Professor Claudio Luchinat at the University of Florence, a co-founder of the Magnetic Resonance Center (CERM), commented: "Metabolite quantification in human urine has proven a challenging task due to complex compositional changes from test person to test person, and even from the same person at different time points. Wet spiking methods according to DIN-norm to detect the limit of detection (LOD) are not delivering sufficient information for safe quantification."
He continued to explain: "With innovative Bruker NMR validation tools it is possible to break this barrier. The new routines introduced for urine quantification also take into account substantial matrix changes going from neonates to children/adults, which all affect metabolite chemical shifts and lead to varying overlap situations due to ionic matrix changes in these two different age classes. We are directly engaged with Bruker in the project to optimize NMR shift prediction."
Dr. Iris Mangelshots, President of Bruker BioSpin's Applied, Industrial & Clinical (AIC) division, confirmed: "Bruker continues to innovate with the introduction of novel and performance-
B.I.QUANT-UR can quantify up to 150 metabolic compounds, including disease markers and non-targeted classification against healthy newborn models, opening new areas of research in frequent diseases such as diabetes, metabolic syndrome and obesity. Additonally, the tool can be used to investigate the role which nutrition and environmental conditions play in health, including functional food efficiency and drug dosage. The IVDr profiling modules B.I.QUANT are for research use only and are not released for clinical diagnostics. For more information visit: www.bruker.com/
About Bruker Corporation
For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, and in microscopy, nano-analysis and industrial applications. In recent years, Bruker has also become a provider of high-performance systems for cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology, and for molecular pathology research.
For more information: